Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.51 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.51 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.50 |
| ▸ | CHUK | O15111 | 3/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toyocamycin Aglycone SCHEMBL7698538 | 0.80 | MAP3K7 (0.54) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL19185239 | 0.79 | MAP3K7 (0.54) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL154683 | 0.79 | CHUK (0.61) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL17401156 | 0.78 | MAP3K7 (0.56) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL26068876 | 0.77 | MAP3K7 (0.40) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL9967152 | 0.75 | AKT1 (0.46) | HSP90AB1ROCK2LRRK2IRAK4 | |
| SCHEMBL14670863 | 0.75 | MAP3K7 (0.52) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL16190651 | 0.74 | LRRK2 (0.67) | HSP90AB1ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL12590787 | 0.73 | CHUK (0.48) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 | |
| SCHEMBL12590786 | 0.73 | MAP3K7 (0.51) | MAP3K7TAB1HSP90AB1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2021198955-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2013012915-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | MAP3K7 33/4885TAB1 606/4885HSP90AB1 811/4885 |
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | MAP3K7 2449/4885TAB1 2926/4885HSP90AB1 1341/4885 |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | MAP3K7 185/4885TAB1 446/4885HSP90AB1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.